The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
M Ahlmann, G Hempel - Cancer chemotherapy and pharmacology, 2016 - Springer
Cyclophosphamide is an alkylating agent belonging to the group of oxazaphosporines. As
cyclophosphamide is in clinical use for more than 40 years, there is a lot of experience using …
cyclophosphamide is in clinical use for more than 40 years, there is a lot of experience using …
Modern approaches to HLA-haploidentical blood or marrow transplantation
CG Kanakry, EJ Fuchs, L Luznik - Nature reviews Clinical oncology, 2016 - nature.com
Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …
treatment for a variety of haematological malignancies and nonmalignant diseases …
National Marrow Donor Program–sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant …
PURPOSE Hematopoietic cell transplantation (HCT) is curative for hematologic disorders,
but outcomes are historically inferior when using HLA-mismatched donors. Despite …
but outcomes are historically inferior when using HLA-mismatched donors. Despite …
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
SR Goldsmith, MB Abid, JJ Auletta… - Blood, The Journal …, 2021 - ashpublications.org
Prior studies suggest increased cytomegalovirus (CMV) infection after haploidentical donor
transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft …
transplantation with posttransplant cyclophosphamide (HaploCy). The role of allograft …
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and …
Background Prevention of graft-versus-host disease (GvHD) without malignant relapse is the
overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate …
overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate …
Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression
LP Wachsmuth, MT Patterson… - The Journal of …, 2019 - Am Soc Clin Investig
Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide
EJ Fuchs, SR McCurdy, SR Solomon… - Blood, The Journal …, 2022 - ashpublications.org
Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly
used to treat hematologic cancers; however, characteristics of the optimal haploidentical …
used to treat hematologic cancers; however, characteristics of the optimal haploidentical …
FOXP3+ regulatory T cells and their functional regulation
Abstract FOXP3+ regulatory T (Treg) cells are critical in maintaining immune tolerance and
homeostasis of the immune system. The molecular mechanisms underlying the stability …
homeostasis of the immune system. The molecular mechanisms underlying the stability …
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
AEC Broers, CN de Jong, K Bakunina… - Blood …, 2022 - ashpublications.org
Graft-versus-host disease (GVHD) is the most important complication of allogeneic
hematopoietic stem cell transplantation (alloHSCT). We performed a prospective …
hematopoietic stem cell transplantation (alloHSCT). We performed a prospective …
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
AS Kanate, A Mussetti… - Blood, The Journal …, 2016 - ashpublications.org
We evaluated 917 adult lymphoma patients who received haploidentical (n= 185) or HLA-
matched unrelated donor (URD) transplantation either with (n= 241) or without …
matched unrelated donor (URD) transplantation either with (n= 241) or without …